Will Mitsubishi's High Offer Price For CNS Target NeuroDerm Deter Others?

Japan's Mitsubishi Tanabe Pharma is offering to buy Israeli CNS specialist NeuroDerm for $1.1bn and the 79% pre-rumor stock price premium may put off other potential suitors.